GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genelux Corp (NAS:GNLX) » Definitions » Total Liabilities

Genelux (Genelux) Total Liabilities : $9.59 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Genelux Total Liabilities?

Genelux's Total Liabilities for the quarter that ended in Mar. 2024 was $9.59 Mil.

Genelux's quarterly Total Liabilities declined from Sep. 2023 ($10.04 Mil) to Dec. 2023 ($8.42 Mil) but then increased from Dec. 2023 ($8.42 Mil) to Mar. 2024 ($9.59 Mil).

Genelux's annual Total Liabilities increased from Dec. 2021 ($41.24 Mil) to Dec. 2022 ($41.31 Mil) but then declined from Dec. 2022 ($41.31 Mil) to Dec. 2023 ($8.42 Mil).

Genelux Total Liabilities Historical Data

The historical data trend for Genelux's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genelux Total Liabilities Chart

Genelux Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Liabilities
36.66 41.24 41.31 8.42

Genelux Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.93 9.11 10.04 8.42 9.59

Genelux Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Genelux's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.554+(1.866+-4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=8.42

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=27.893-19.473
=8.42

Genelux's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.805+(1.787+8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=9.59

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=24.676-15.084
=9.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genelux Total Liabilities Related Terms

Thank you for viewing the detailed overview of Genelux's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Genelux (Genelux) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genelux Corp (NAS:GNLX) » Definitions » Total Liabilities
Comparable Companies
EWTX LYEL LQDA ANTX CGEM ANAB TSHA DYN RNA FDMT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
2625 Townsgate Road, Suite 230, Westlake Village, CA, USA, 91361
Website
https://www.genelux.com
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
Executives
Tony Yu officer: VP, Clinical Trial Operations C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
John Thomas director C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Aladar Szalay 10 percent owner C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Sean Ryder officer: General Counsel C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
John W Smither director C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Lourie S. Zak officer: Chief Financial Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Thomas Zindrick director, officer: President and CEO C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE. 230, WESTLAKE VILLAGE CA 91361
Joseph Cappello officer: VP, Pharmaceutical Development C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Doug Samuelson officer: Chief Financial Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Caroline Jewett officer: Head of Quality C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Ralph Smalling officer: Head of Regulatory C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Qian Zhang officer: Associate VP, Research C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Mary Mirabelli director C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Paul Scigalla officer: Chief Medical Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361